The Food and Drug Administration is about to decide whether a scientific word can become a regulatory loophole.
On July 23 and 24, the FDA’s Pharmacy Compounding Advisory Committee is scheduled to consider whether several peptides should be added to the list of bulk drug substances that may be used in pharmacy compounding. That sounds technical. It is not. The decision could help determine whether a fast-growing wellness market is brought under disciplined medical oversight or whether compounding becomes a back door around the ordinary drug-approval process.
The debate should start with a simple point: There is nothing inherent in a peptide that makes it exempt from ordinary questions of safety, efficacy, dosing, purity, adverse effects, and long-term risk.
Peptides are short chains of amino acids. Some are naturally occurring or resemble molecules the body uses for signaling. But that does not make them harmless. Many peptides are biologically active precisely because they alter human physiology. That is why some peptides have become important medicines.
Insulin is a peptide. GLP-1 agonists such as Ozempic and Wegovy are peptide-based drugs. No one would argue that those products should have reached patients without rigorous review simply because they are peptides. Their value depends on evidence, manufacturing controls, dosing standards, labeling, and postmarket monitoring. The same logic should apply to newer peptides promoted for inflammation, injury recovery, metabolism, sleep, sexual function, pain, or anti-aging.
Supporters of broader access make one fair point. The current gray market is real. Consumers are already buying “research use only” products online, often with uncertain sourcing, identity, sterility, potency, and dosing. Some products come from overseas suppliers. Some are promoted by influencers, longevity clinics, med spas, telehealth platforms, and fitness communities. Patients who are determined to obtain these substances may be safer with a regulated pharmacy than with an anonymous vial purchased online.
But consumer demand is not clinical evidence. Nor is the existence of a black market, by itself, a reason to create a legal market before safety and efficacy are established. That logic would prove too much. If demand alone justified medical normalization, then illicit popularity could become an argument for distributing almost any widely sought drug first and studying it later.
That is not how a serious medical system works.
Compounding has an important role in American medicine. It allows pharmacists to meet legitimate patient needs when a commercially available product cannot. A child may need a liquid formulation because he cannot swallow a pill. A patient may need a medication without dyes, preservatives, or excipients that cause an allergy. A drug shortage may create a temporary need for compounded alternatives. Properly used, compounding is a practical exception that helps individual patients.
It was not designed to become a parallel drug-approval pathway.
That distinction is the heart of the peptide issue. Patient-specific compounding is one thing. Mass commercial distribution of pharmacologically active wellness products, without the evidence expected of drugs, is another. The more peptides are sold through subscriptions, spas, gyms, telehealth portals, and longevity clinics, the less this resembles individualized medicine and the more it resembles ordinary drug marketing without ordinary drug development.
The retatrutide controversy shows where this mindset leads. Retatrutide is an experimental weight-loss drug that has not been FDA-approved. Yet clinics and online sellers have already promoted it to consumers, with some arguing that the trial data look promising enough and that patients should not have to wait. But waiting for an independent review is not bureaucratic superstition. It is the mechanism by which we learn whether a product is safe, effective, correctly dosed, appropriately labeled, and reliably manufactured.
Conservatives should not be afraid to say this. Opposing regulatory sclerosis is not the same as endorsing regulatory surrender. The FDA can be too slow, too rigid, too hostile to innovation, and too opaque. Patients with serious illnesses often have good reason to resent unnecessary delay. But none of that means influencer demand or political enthusiasm should substitute for evidence.
The FDA should therefore be clear about what path it is choosing. If it permits broader peptide compounding, it should define the permitted uses, require credible sourcing and quality controls, distinguish patient-specific medicine from commercial wellness marketing, and explain what constitutes sufficient evidence. It should also make clear that placement on a compounding list is not the same as FDA approval.
WHITE HOUSE DENIES REPORT TRUMP GOT ACCESS TO EXPERIMENTAL WEIGHT LOSS DRUG
Peptides may be promising. Some may eventually become important therapies. Some may justify narrow, carefully controlled compounding. But the word “peptide” should not function as a scientific halo. If a compound is powerful enough to treat disease, alter metabolism, or change human physiology, it is powerful enough to harm.
The FDA should not create peptide exceptionalism. It should demand peptide evidence.
Arie Blitz, MD, MBA, is a retired physician and independent writer in Weslaco, Texas.